Review





Similar Products

94
MedChemExpress mouse recombinant vegfc
Mouse Recombinant Vegfc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pm42044813-65-13-16?v=MedChemExpress
Average 94 stars, based on 1 article reviews
mouse recombinant vegfc - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

97
PromoCell vegf 165
Vegf 165, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pm41903119-261-5-11?v=PromoCell
Average 97 stars, based on 1 article reviews
vegf 165 - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier

86
Jingmei Biotech Co Ltd relevant parameters vegf c
Relevant Parameters Vegf C, supplied by Jingmei Biotech Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pm42156495-112-20-25?v=Jingmei+Biotech+Co+Ltd
Average 86 stars, based on 1 article reviews
relevant parameters vegf c - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

94
R&D Systems vegfc
Vegfc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pm41944190-231-16-17?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
vegfc - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
Biosynth Carbosynth purified recombinant rat vegf c protein 152s
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Purified Recombinant Rat Vegf C Protein 152s, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pmc13012992-75-20-26?v=Biosynth+Carbosynth
Average 94 stars, based on 1 article reviews
purified recombinant rat vegf c protein 152s - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
R&D Systems recombinant human vegf c c156s
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Recombinant Human Vegf C C156s, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pm41797259-55-0-4?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant human vegf c c156s - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc antibodies against vegf
Validation of GMN-GSE multifunctional hydrogel scaffolds to promote “H”-shaped vessel regeneration. (A) EPCs tube-forming assay. (B, C) Quantitative analysis related to tube formation assay. (D) Quantitative analysis <t>of</t> <t>CD31</t> staining (red). (E) Immunofluorescence staining of EPCs for DAPI (blue), ghost pen cyclic peptide (green), and CD31 (red). (F) Protein blotting assay and quantitative analysis of <t>VEGF</t> and CD31.
Antibodies Against Vegf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/pmc12661998-175-5-9?v=Cell+Signaling+Technology+Inc
Average 94 stars, based on 1 article reviews
antibodies against vegf - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

86
Novoprotein recombinant vegf c protein
Validation of GMN-GSE multifunctional hydrogel scaffolds to promote “H”-shaped vessel regeneration. (A) EPCs tube-forming assay. (B, C) Quantitative analysis related to tube formation assay. (D) Quantitative analysis <t>of</t> <t>CD31</t> staining (red). (E) Immunofluorescence staining of EPCs for DAPI (blue), ghost pen cyclic peptide (green), and CD31 (red). (F) Protein blotting assay and quantitative analysis of <t>VEGF</t> and CD31.
Recombinant Vegf C Protein, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+c/10__3390_slash_cimb48030259-194-0-14?v=Novoprotein
Average 86 stars, based on 1 article reviews
recombinant vegf c protein - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Journal: Frontiers in Cardiovascular Medicine

Article Title: Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice

doi: 10.3389/fcvm.2026.1699372

Figure Lengend Snippet: VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Article Snippet: Mice received intraperitoneal (IP) injections of VEGF-C (152s) at a dose of 50 ng per 25 g of body weight [purified recombinant rat VEGF-C protein (152s), Fitzgerald, catalog no. 30R-AV006-22] or vehicle control (phosphate-buffered saline, PBS), administered three times per week for four consecutive weeks.

Techniques: Clinical Proteomics, Intravital Microscopy, Staining

Validation of GMN-GSE multifunctional hydrogel scaffolds to promote “H”-shaped vessel regeneration. (A) EPCs tube-forming assay. (B, C) Quantitative analysis related to tube formation assay. (D) Quantitative analysis of CD31 staining (red). (E) Immunofluorescence staining of EPCs for DAPI (blue), ghost pen cyclic peptide (green), and CD31 (red). (F) Protein blotting assay and quantitative analysis of VEGF and CD31.

Journal: Bioactive Materials

Article Title: 3D printed scaffolds regulated by neural-bone metabolic coupling promote bone unit regeneration

doi: 10.1016/j.bioactmat.2025.10.031

Figure Lengend Snippet: Validation of GMN-GSE multifunctional hydrogel scaffolds to promote “H”-shaped vessel regeneration. (A) EPCs tube-forming assay. (B, C) Quantitative analysis related to tube formation assay. (D) Quantitative analysis of CD31 staining (red). (E) Immunofluorescence staining of EPCs for DAPI (blue), ghost pen cyclic peptide (green), and CD31 (red). (F) Protein blotting assay and quantitative analysis of VEGF and CD31.

Article Snippet: Membranes were incubated with primary antibodies against VEGF (1:1000, CST), CD31 (1:500, Abcam), and β-actin (1:5000, Sigma), followed by HRP-conjugated goat anti-rabbit IgG secondary antibody (1:5000, Abcam).

Techniques: Biomarker Discovery, Tube Formation Assay, Staining, Immunofluorescence